Urine tests may be better than serum tests to diagnose multiple myeloma or its precursor conditions, because they can spot cases that would be missed by serum screenings, a study has found. Serum free light chain tests may fail to diagnose about…
Twice‐weekly Ninlaro (ixazomib) plus Revlimid (lenalidomide) and dexamethasone can improve long-term outcomes in patients with newly diagnosed multiple myeloma, although it’s likely more toxic than once-weekly Ninlaro, according to the results from a Phase 1/2 trial. The findings were…
Adding Pomalyst (pomalidomide) to a combination of Velcade (bortezomib) and dexamethasone significantly extended the time until disease worsening or death in patients with relapsed or refractory multiple myeloma, updated Phase 3 trial data shows. The trial, called …
The University of Alabama at Birmingham (UAB) is recruiting patients with newly diagnosed multiple myeloma for a Phase 2 trial evaluating an innovative treatment approach with the goal of completely eradicating the disease. Led by UAB researchers, the clinical trial, called MASTER (…
Selinexor, the lead oral therapy developed by Karyopharm Therapeutics, received Fast Track designation by the U.S. Food and Drug Administration (FDA), for the treatment of refractory…
SELLAS Life Sciences’ Galinpepimut-S vaccine more than doubles the time it takes for high-risk multiple myeloma patients’ cancer to worsen, a Phase 2 clinical trial shows. Myeloma expert Guenther Koehne presented the results at the Annual Meeting of the European Society for Blood and Marrow Transplantation in Lisbon, Portugal,…
Immune factors that drive donor T-cells to cause graft-versus-host disease (GVHD) have been found by researchers whose discovery may offer new opportunities for therapeutic targets to minimize the risks of stem cell transplants. High-dose therapy with melphalan followed by autologous stem cell…
Get regular updates to your inbox.